Cancer risk and chemoprevention in Chinese inflammatory bowel disease patients: a population-based cohort study. (3rd March 2020)

• Record Type: Journal Article
• Authors: Mak, Joyce Wing Yan; So, Jacqueline; Tang, Whitney; Yip, Terry Cheuk Fung; Leung, Wai Keung; Li, Michael; Lo, Fu Hang; Ng, Ka Man; Sze, Shun Fung; Leung, Chi Man; Tsang, Steven Woon Choy; Shan, Edwin Hok Shing; Chan, Kam Hon; Lam, Belsy C.Y.; Hui, Aric J.; Chow, Wai Hung; Chan, Francis Ka Leung; Ng, Siew Chien
• Is Part Of: Scandinavian journal of gastroenterology. Volume 55:Number 3(2020)
• Page Start: 279
• Page End: 286
• Publication Date: 2020-03-03
• Subjects: 5- aminosalicylic acid -- aspirin -- statin -- cancer -- IBD; Gastroenterology -- Periodicals; Digestive organs -- Diseases -- Periodicals; 616.33
• DOI: 10.1080/00365521.2020.1731760
• Languages: English
• ISSNs: 0036-5521

Abstract

Abstract: Background and aim: Role of 5-aminosalicylic acid (5-ASA), statin and aspirin in reducing cancer risks in inflammatory bowel disease (IBD) remains controversial. We aimed to examine chemo-preventive effects of these drugs in all cancers in IBD in population-based setting. Methods: IBD patients diagnosed between 2000 and 2016 were identified from the Hong Kong IBD Registry and followed from IBD diagnosis until first cancer occurrence. Primary outcome was cancer development ≥6 months after IBD diagnosis. Adjusted hazard ratio (aHR) with 95% confidence interval (CI) was estimated with Cox proportional hazards model. Additional effects of statin and aspirin on chemoprevention were also assessed. Results: Amongst 2103 IBD patients (857 Crohn's disease, 1246 ulcerative colitis; mean age 40.0 ± 15.6; 60.3% male) with 16, 856 person-years follow-up, 48 patients (2.3%) developed cancer. The 5-r, 10-r and 15-year (95% CI) cumulative incidence of cancer were 1% (0.6 − 1.5%), 2.8 (2.0 − 3.9%) and 4.8 (3.4 − 6.5%), respectively. Total 1891 (89.9%) and 222 (10.6%) patients have received one or more prescriptions of 5-ASA and statin respectively. In multivariable analysis adjusted for age, gender, smoking status, IBD type and use of other medications, use of 5-ASA or statin was not associated with a reduced risk of cancer development (5-ASA: aHR 1.22, 95% CI: 0.60–2.48, p = .593; statin: aHR 0.48, 95% CI: 0.14–1.59, p = .227). Adding aspirin was not associated with a lowered cancer risk (aHR 1.18, 95% CI: 0.32–4.35, p = .799). Conclusion: Use of 5-ASA was not associated with a lowered cancer risk in Chinese IBD patients. Addition of statin/aspirin provided no additional benefit. Key summary: Inflammatory bowel diseases (IBD) including Crohn's disease and ulcerative colitis are associated with increased risk of both intestinal and extra- intestinal cancers. Various medications including 5-aminosalicylate acid (5-ASA), statins and aspirin have been studied for their chemoprevention effects. However, most studies focused on colorectal cancer only and showed conflicting evidence. No studies so far looked at the effects of these medications on all cancer development in IBD. The 5-, 10- and 15-year (95% confidence interval) cumulative incidence of cancer in Chinese IBD patients were 1 (0.6–1.5%), 2.8 (2.0–3.9%) and 4.8 (3.4–6.5%), respectively. Use of 5-ASA was not associated with a lowered cancer risk in Chinese IBD patients. Addition of statin/aspirin provided no additional benefit.